Foghorn Therapeutics cut to neutral from buy at BTIG
FHTX•BTIG cut its rating on Foghorn Therapeutics to neutral from buy.
Related News
Borr Drilling reports PDMR transactions tied to long-term incentive program
BORR•
Samsara EVP, CTO John Bicket disposes of 264,784 common shares worth $10.05 million
IOT•
Moderna to join Nasdaq-100, replacing Warner Bros. Discovery on Oct. 9
MRNA•
Gold steadies before US payrolls data, set for second weekly loss
GLD•
Allegro Microsystems initiated with outperform rating and $50 target price
ALGM•